FDA Approves Lilly’s Zepbound TM (tirzepatide) for Chronic Weight Management

A powerful new option for the treatment of obesity or overweight with weight-related Medical problems. The first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucanon-like peptide-1) hormone receptors, it should be used with a reduced-calorie diet and increase physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agoinst medicines and it has not been studies in patient with a history of pancreatitis or with severe gastrointestinal disefor Chronic weight managments, incuiding severe gastroparentesis. Zepbound is an injectable prescription medicine espected to be available in the U.S by the end of the year in six doses at a list price of $1059.87